ExploreWatchlistsPricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Gross profit

ReproCELL Incorporated (4978)

Market cap
¥11.9B
P/E ratio
-26.1x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross profit (Million JPY)YoY (%)
Mar 31, 20261,015-38.43%
Mar 31, 20251,649+47.11%
Mar 31, 20241,121-1.78%
Mar 31, 20231,141+42.05%
Mar 31, 2022803+66.45%
Mar 31, 2021483+1.68%
Mar 31, 2020475-4.38%
Mar 31, 2019496+30.23%
Mar 31, 2018381-33.83%
Mar 31, 2017576+8.09%
Mar 31, 2016533+93.06%
Mar 31, 2015276

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat